

CV Sciences Certificate of Analysis



This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.

SAMPLE ID:**PRODUCT NAME:**

Strength:

Lot Number:

Expiration Date:

CANNABINOIDS***MG/UNIT****METHOD**

CBD

CBDA

d9-THC

THCA-A

d8-THC

THCV

CBDV

CBDVA

CBGA

CBG

CBN

CBC

CBL

Total Cannabinoids

Sample Size

THC by Mass

HEAVY METALS***STATUS (PASS/FAIL)****METHOD**

Arsenic

Cadmium

Mercury

Lead

CV Sciences Certificate of Analysis



MICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
Mold/Mildew/Yeast		
Aerobic Bacteria		
Coliforms		
E. Coli		
Salmonella		
Pseudomonas		

PESTICIDES**	STATUS (PASS/FAIL)	METHOD
Total Pesticides		
Mycotoxins	Pass	

RESIDUAL SOLVENTS**	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

1. The hemp extract is the product of a batch tested by the independent testing laboratory;
2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
3. The batch does not contain contaminants unsafe for human consumption.[†]


[†]Tested analytes and limits were set by CV Sciences, Inc.

DB Labs Sample ID #:

*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

Anresco Laboratories Sample ID #:

**Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.

QUALITY APPROVAL		
Prepared By / Date	Approved By / Date	Status
Joseph Dowling	<div><div>Signed by Joseph Dowling</div><div> Joseph Dowling</div><div>I approve this document 28-Apr-2025 13:23 PDT</div><div>1FB515412DDF4F85A71FF07E156C6F48</div></div>	




April 24, 2025

CV SCIENCES, INC.9530 Padgett Street, Suite 107
San Diego, CA 92126Order No. 570817
Sample No. 1298971

SAMPLE INFORMATION

Description IP-25-0008 Reserve liquid lemon ginger 1floz 750mg -1
Lot Number 52650
Category (Type) Non-Inhalable Edible (Tincture)
Received April 23, 2025

ANALYTICAL RESULTS

Analysis Cannabinoid Profile (Non-Plant)  **Pass**
Instrument Liquid Chromatography Diode Array Detector (LC-DAD)
Method MF-CHEM-15
Analysis Date April 23, 2025 to April 24, 2025

Cannabinoid	mg/g	%	mg/ml	mg/serving	mg/package	Labeled mg/serving	% Difference	Status
Δ8-THC	ND	ND	ND	ND	ND	-	-	-
Δ9-THC	2.74	0.274	2.51	2.51	75.16	2.5	0.21	Pass
Δ9-THCA	ND	ND	ND	ND	ND	-	-	-
THCV	ND	ND	ND	ND	ND	-	-	-
THCVA	ND	ND	ND	ND	ND	-	-	-
CBD	27.53	2.753	25.17	25.17	755.01	25	0.67	-
CBDA	ND	ND	ND	ND	ND	-	-	-
CBC	ND	ND	ND	ND	ND	-	-	-
CBCA	ND	ND	ND	ND	ND	-	-	-
CBDV	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
CBG	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
CBGA	ND	ND	ND	ND	ND	-	-	-
CBN	ND	ND	ND	ND	ND	-	-	-
Total THC	2.74	0.274	2.51	2.51	75.16	-	-	-
Total CBD	27.53	2.753	25.17	25.17	755.01	-	-	-
Total Cannabinoids	30.27	3.027	27.67	27.67	830.17	-	-	-
Sum of Cannabinoids	30.27	3.027	27.67	27.67	830.17	-	-	-
Serving Weight (g)	0.9142							
Package Weight (g)	27.426							
g/ml Conversion Factor	0.9142							

Reported by
Anresco, Inc.

NT = Not Tested
ND = None Detected
LOD = Limit of Detection (0.067 mg/g)
LOQ = Limit of Quantitation (0.2 mg/g)
Total THC = Δ8-THC + Δ9-THC + (0.877 * THCA)
Total CBD = CBD + (0.877 * CBDA)
Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 * Σ (acidic cannabinoids)]


Ali Sweeney
Analyst II

April 24, 2025

If there are any questions with this report, please contact "compliance@anresco.com".


April 24, 2025

CV SCIENCES, INC.9530 Padgett Street, Suite 107
San Diego, CA 92126Order No. 570817
Sample No. 1298972

SAMPLE INFORMATION

Description IP-25-0009 Reserve liquid lemon ginger 1floz 750mg -2
Lot Number 52650
Category (Type) Non-Inhalable Edible (Tincture)
Received April 23, 2025


ANALYTICAL RESULTS

Analysis Cannabinoid Profile (Non-Plant)  **Pass**
Instrument Liquid Chromatography Diode Array Detector (LC-DAD)
Method MF-CHEM-15
Analysis Date April 23, 2025 to April 24, 2025

Cannabinoid	mg/g	%	mg/ml	mg/serving	mg/package	Labeled mg/serving	% Difference	Status
Δ8-THC	ND	ND	ND	ND	ND	-	-	-
Δ9-THC	2.74	0.274	2.50	2.50	75.03	2.5	0.04	Pass
Δ9-THCA	ND	ND	ND	ND	ND	-	-	-
THCV	ND	ND	ND	ND	ND	-	-	-
THCVA	ND	ND	ND	ND	ND	-	-	-
CBD	27.62	2.762	25.24	25.24	757.19	25	0.96	-
CBDA	ND	ND	ND	ND	ND	-	-	-
CBC	ND	ND	ND	ND	ND	-	-	-
CBCA	ND	ND	ND	ND	ND	-	-	-
CBDV	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
CBG	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
CBGA	ND	ND	ND	ND	ND	-	-	-
CBN	ND	ND	ND	ND	ND	-	-	-
Total THC	2.74	0.274	2.50	2.50	75.03	-	-	-
Total CBD	27.62	2.762	25.24	25.24	757.19	-	-	-
Total Cannabinoids	30.35	3.035	27.74	27.74	832.22	-	-	-
Sum of Cannabinoids	30.35	3.035	27.74	27.74	832.22	-	-	-
Serving Weight (g)	0.9139							
Package Weight (g)	27.417							
g/ml Conversion Factor	0.9139							

Reported by
Anresco, Inc.

NT = Not Tested
ND = None Detected
LOD = Limit of Detection (0.067 mg/g)
LOQ = Limit of Quantitation (0.2 mg/g)
Total THC = Δ8-THC + Δ9-THC + (0.877 * THCA)
Total CBD = CBD + (0.877 * CBDA)
Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 * Σ (acidic cannabinoids)]


Ali Sweeney
Analyst II

April 24, 2025

If there are any questions with this report, please contact "compliance@anresco.com".



Certificate of Analysis

April 24, 2025


CV SCIENCES, INC.
9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 570817
Sample No. 1298973

SAMPLE INFORMATION

Description IP-25-0010 Reserve liquid lemon ginger 1floz 750mg -3
Lot Number 52650
Category (Type) Non-Inhalable Edible (Tincture)
Received April 23, 2025

ANALYTICAL RESULTS

Analysis Cannabinoid Profile (Non-Plant)  **Pass**
Instrument Liquid Chromatography Diode Array Detector (LC-DAD)
Method MF-CHEM-15
Analysis Date April 23, 2025 to April 24, 2025

Cannabinoid	mg/g	%	mg/ml	mg/serving	mg/package	Labeled mg/serving	% Difference	Status
Δ8-THC	ND	ND	ND	ND	ND	-	-	-
Δ9-THC	2.76	0.276	2.52	2.52	75.55	2.5	0.74	Pass
Δ9-THCA	ND	ND	ND	ND	ND	-	-	-
THCV	ND	ND	ND	ND	ND	-	-	-
THCVA	ND	ND	ND	ND	ND	-	-	-
CBD	27.46	2.746	25.10	25.10	752.98	25	0.40	-
CBDA	ND	ND	ND	ND	ND	-	-	-
CBC	ND	ND	ND	ND	ND	-	-	-
CBCA	ND	ND	ND	ND	ND	-	-	-
CBDV	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
CBG	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
CBGA	ND	ND	ND	ND	ND	-	-	-
CBN	ND	ND	ND	ND	ND	-	-	-
Total THC	2.76	0.276	2.52	2.52	75.55	-	-	-
Total CBD	27.46	2.746	25.10	25.10	752.98	-	-	-
Total Cannabinoids	30.22	3.022	27.62	27.62	828.53	-	-	-
Sum of Cannabinoids	30.22	3.022	27.62	27.62	828.53	-	-	-
Serving Weight (g)	0.9139							
Package Weight (g)	27.417							
g/ml Conversion Factor	0.9139							

Reported by
Anresco, Inc.


Ali Sweeney
Analyst II

April 24, 2025



NT = Not Tested
ND = None Detected
LOD = Limit of Detection (0.067 mg/g)
LOQ = Limit of Quantitation (0.2 mg/g)
Total THC = Δ8-THC + Δ9-THC + (0.877 * THCA)
Total CBD = CBD + (0.877 * CBDA)
Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 * Σ (acidic cannabinoids)]

If there are any questions with this report, please contact "compliance@anresco.com".



Certificate of Analysis

April 24, 2025

CV SCIENCES, INC.
9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 570817
Sample No. 1298974

SAMPLE INFORMATION

Description IP-25-0011 Reserve liquid lemon ginger 1floz 750mg -4
Lot Number 52650
Category (Type) Non-Inhalable Edible (Tincture)
Received April 23, 2025

ANALYTICAL RESULTS

Analysis Cannabinoid Profile (Non-Plant) **Pass**
Instrument Liquid Chromatography Diode Array Detector (LC-DAD)
Method MF-CHEM-15
Analysis Date April 23, 2025 to April 24, 2025

Cannabinoid	mg/g	%	mg/ml	mg/serving	mg/package	Labeled mg/serving	% Difference	Status
Δ8-THC	ND	ND	ND	ND	ND	-	-	-
Δ9-THC	2.76	0.276	2.52	2.52	75.73	2.5	0.98	Pass
Δ9-THCA	ND	ND	ND	ND	ND	-	-	-
THCV	ND	ND	ND	ND	ND	-	-	-
THCVA	ND	ND	ND	ND	ND	-	-	-
CBD	27.37	2.737	25.03	25.03	750.96	25	0.13	-
CBDA	ND	ND	ND	ND	ND	-	-	-
CBC	ND	ND	ND	ND	ND	-	-	-
CBCA	ND	ND	ND	ND	ND	-	-	-
CBDV	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
CBG	<LOQ	<LOQ	<LOQ	<LOQ	<LOQ	-	-	-
CBGA	ND	ND	ND	ND	ND	-	-	-
CBN	ND	ND	ND	ND	ND	-	-	-
Total THC	2.76	0.276	2.52	2.52	75.73	-	-	-
Total CBD	27.37	2.737	25.03	25.03	750.96	-	-	-
Total Cannabinoids	30.13	3.013	27.56	27.56	826.69	-	-	-
Sum of Cannabinoids	30.13	3.013	27.56	27.56	826.69	-	-	-
Serving Weight (g)	0.9147							
Package Weight (g)	27.441							
g/ml Conversion Factor	0.9147							

Reported by
Anresco, Inc.


Ali Sweeney
Analyst II

April 24, 2025



NT = Not Tested
ND = None Detected
LOD = Limit of Detection (0.067 mg/g)
LOQ = Limit of Quantitation (0.2 mg/g)
Total THC = Δ8-THC + Δ9-THC + (0.877 * THCA)
Total CBD = CBD + (0.877 * CBDA)
Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 * Σ (acidic cannabinoids)]

If there are any questions with this report, please contact "compliance@anresco.com".

April 22, 2025

CV SCIENCES, INC.9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 570475

Sample No. 1297352

SAMPLE INFORMATION

Description FP-25-0031 Reserve liquid lemon ginger 1floz 750mg SKU 618 exp 04/27
Lot Number 52650
Category (Type) Non-Inhalable Edible (Tincture)
Received April 18, 2025

ANALYTICAL RESULTS

Analysis Pesticide Screen ✔ Pass
Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method MF-CHEM-13
Analysis Date April 18, 2025 to April 22, 2025

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.017/0.05	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.017/0.05	ND	0.017	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.06	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.017/0.05	ND	0.017	Pass
DDVP (Dichlorvos)	0.013/0.04	ND	0.013	Pass
Diazinon	0.017/0.05	ND	0.2	Pass
Dimethoate	0.017/0.05	ND	0.017	Pass
Dimethomorph	0.017/0.05	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.017/0.05	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "compliance@anresco.com".

Certificate of Analysis

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.017/0.05	ND	5.0	Pass
Metalaxyl	0.017/0.05	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.013/0.04	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.017/0.05	ND	0.5	Pass
Oxamyl	0.013/0.04	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.017/0.05	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.017/0.05	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.013/0.04	ND	0.013	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.017/0.05	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.017/0.05	ND	0.017	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiacloprid	0.013/0.04	ND	0.013	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Reported by
Anresco, Inc.

NT = Not Tested
 ND = None Detected
 LOD = Limit of Detection
 LOQ = Limit of Quantitation

Angela Zhu
 Analyst I



April 22, 2025

If there are any questions with this report, please contact "compliance@anresco.com".

April 22, 2025

CV SCIENCES, INC.9530 Padgett Street, Suite 107
San Diego, CA 92126Order No. 570475
Sample No. 1297352

SAMPLE INFORMATION

Description FP-25-0031 Reserve liquid lemon ginger 1floc 750mg SKU 618 exp 04/27
Lot Number 52650
Category (Type) Non-Inhalable Edible (Tincture)
Received April 18, 2025

ANALYTICAL RESULTS

Analysis Residual Solvent Screen ✔ Pass
Instrument Gas Chromatography Mass Spectrometry (GC/MS)
Method MF-CHEM-32
Analysis Date April 18, 2025 to April 22, 2025

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.5/0.5	ND	1	Pass
Acetone	57/200	ND	5000	Pass
Acetonitrile	56/200	ND	410	Pass
Benzene	0.5/0.5	ND	1	Pass
n-Butane	45/200	ND	5000	Pass
Chloroform	0.5/0.5	ND	1	Pass
Ethanol	37/200	14000.00	Not Applicable	Pass
Ethyl acetate	38/200	ND	5000	Pass
Ethyl ether	37/200	ND	5000	Pass
Ethylene oxide	0.1/0.5	ND	1	Pass
n-Heptane	135/200	ND	5000	Pass
n-Hexane	49/200	ND	290	Pass
Isopropyl alcohol	57/200	ND	5000	Pass
Methanol	37/200	ND	3000	Pass
Methylene chloride	0.1/0.5	ND	1	Pass
n-Pentane	37/200	ND	5000	Pass
Propane	72/200	ND	5000	Pass
Toluene	49/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	58/200	ND	2170	Pass
Trichloroethylene	0.5/0.5	ND	1	Pass

Reported by
Anresco, Inc.

NT = Not Tested
ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation


Alma Dorantes
Analyst I
April 22, 2025



If there are any questions with this report, please contact "compliance@anresco.com".



Certificate of Analysis

April 22, 2025

CV SCIENCES, INC.
9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 570475
Sample No. 1297352

SAMPLE INFORMATION

Description FP-25-0031 Reserve liquid lemon ginger 1floz 750mg SKU 618 exp 04/27
Lot Number 52650
Category (Type) Non-Inhalable Edible (Tincture)
Received April 18, 2025

ANALYTICAL RESULTS

Analysis Mycotoxins Screen ✔ Pass
Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method MF-CHEM-13
Analysis Date April 18, 2025 to April 22, 2025

Analyte	LOD/LOQ (ppb)	Findings (ppb)	Limit (ppb)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/18	ND	20	Pass

Reported by
Anresco, Inc.

NT = Not Tested
ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation


Angela Zhu
Analyst I
April 22, 2025



If there are any questions with this report, please contact "compliance@anresco.com".

April 25, 2025

CV SCIENCES, INC.

9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 570475
Sample No. 1297352

SAMPLE INFORMATION

Description FP-25-0031 Reserve liquid lemon ginger 1 floz 750mg SKU 618 exp 04/27
Lot Number 52650
Received April 18, 2025

ANALYTICAL RESULTS

Analysis Date April 18, 2025 to April 25, 2025

Findings	Analysis	Results	Method
	Standard Plate Count	<10 cfu/g	FDA BAM
	Yeast	<10 cfu/g	FDA BAM
	Mold	<10 cfu/g	FDA BAM
	Coliforms	<10 cfu/g	FDA BAM - ECC AGAR
	Escherichia coli	<10 cfu/g	FDA BAM - ECC AGAR
	Salmonella	Negative /10g	MF-MICRO-11 (AOAC 2016.01)

Reported by
Anresco, Inc.



Allen Zhu
Analyst

If there are any questions with this report, please contact "compliance@anresco.com".

page 1 of 1

April 22, 2025

CV SCIENCES, INC.

9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 570475
Sample No. 1297352

SAMPLE INFORMATION

Description FP-25-0031 Reserve liquid lemon ginger 1floz 750mg SKU 618 exp 04/27
Lot Number 52650
Category (Type) Non-Inhalable Edible (Tincture)
Received April 18, 2025

ANALYTICAL RESULTS

Analysis Heavy Metals ✔ Pass
Instrument Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
Method MF-CHEM-16
Analysis Date April 18, 2025 to April 22, 2025

Analyte	LOD/LOQ (µg/g)	Findings (µg/g)	Limit (µg/g)	Status
Arsenic	0.003/0.05	ND	1.5	Pass
Cadmium	0.008/0.05	ND	0.5	Pass
Mercury	0.002/0.05	ND	3	Pass
Lead	0.01/0.125	<LOQ	0.5	Pass

Reported by
Anresco, Inc.

NT = Not Tested
ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation



Eric Tam
Senior Chemist

April 22, 2025

If there are any questions with this report, please contact "compliance@anresco.com".

Certificate Of Completion

Envelope Id: 34FE9481-C835-4CE0-9AAC-410264337B07

Status: Completed

Subject: FP-25-0031 Reserve liquid lemon ginger 1floz 750mg SKU 618 LOT 52650.pdf

Source Envelope:

Document Pages: 12

Signatures: 1

Envelope Originator:

Certificate Pages: 5

Initials: 1

Vandana Kothari

AutoNav: Enabled

vandana.kothari@cvsciences.com

Envelopeld Stamping: Enabled

IP Address: 64.207.219.71

Time Zone: (UTC-08:00) Pacific Time (US & Canada)

Record Tracking

Status: Original

Holder: Vandana Kothari

Location: DocuSign

4/28/2025 9:28:13 AM

vandana.kothari@cvsciences.com

Signer Events

Signature

Timestamp

Joseph Dowling

joseph.dowling@cvsciences.com

CEO

CV Sciences, Inc.

Security Level: Email, Account Authentication (Required)

Joseph Dowling

Signature Adoption: Pre-selected Style

Signature ID:

1FB51541-2DDF-4F85-A71F-F07E156C6F48

Using IP Address: 107.132.215.12

Sent: 4/28/2025 9:29:30 AM

Resent: 4/28/2025 1:22:34 PM

Viewed: 4/28/2025 1:23:23 PM

Signed: 4/28/2025 1:25:24 PM

With Signing Authentication via Docusign password

With Signing Reasons (on each tab):

I approve this document

Electronic Record and Signature Disclosure:

Accepted: 4/28/2025 1:23:23 PM

ID: c5cf80cc-d8cc-450f-92e2-985222fbcc03

Vandana Kothari

vandana.kothari@cvsciences.com

DIRECTOR OF QUALITY

CV Sciences - Part 11

Security Level: Email, Account Authentication (Required)

Vandana Kothari

Signature Adoption: Pre-selected Style

Signature ID:

87A410FF-F032-4873-8900-BEED0868E359

Using IP Address: 75.85.176.253

Sent: 4/28/2025 9:29:29 AM

Viewed: 4/28/2025 9:30:07 AM

Signed: 4/28/2025 9:31:00 AM

With Signing Authentication via Docusign password

With Signing Reasons (on each tab):

I approve this document

Electronic Record and Signature Disclosure:

Not Offered via Docusign

In Person Signer Events

Signature

Timestamp

Editor Delivery Events

Status

Timestamp

Agent Delivery Events

Status

Timestamp

Intermediary Delivery Events

Status

Timestamp

Certified Delivery Events

Status

Timestamp

Carbon Copy Events

Status

Timestamp

Witness Events	Signature	Timestamp
----------------	-----------	-----------

Notary Events	Signature	Timestamp
---------------	-----------	-----------

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	4/28/2025 9:29:30 AM
Certified Delivered	Security Checked	4/28/2025 9:30:07 AM
Signing Complete	Security Checked	4/28/2025 9:31:00 AM
Completed	Security Checked	4/28/2025 1:25:24 PM

Payment Events	Status	Timestamps
----------------	--------	------------

Electronic Record and Signature Disclosure
--

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, CV Sciences - Part 11 (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact CV Sciences - Part 11:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: vandana.kothari@cvsciences.com

To advise CV Sciences - Part 11 of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at vandana.kothari@cvsciences.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from CV Sciences - Part 11

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to vandana.kothari@cvsciences.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with CV Sciences - Part 11

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to vandana.kothari@cvsciences.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify CV Sciences - Part 11 as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by CV Sciences - Part 11 during the course of your relationship with CV Sciences - Part 11.